Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

It has been suggested that the therapeutic efficacy of S-1 + cisplatin (SP) and capecitabine + cisplatin (XP) may differ depending on the histology of the tumor, but no clear evidence exists. Individual participant data were obtained from three randomized phase II trials in which such patients recei...

Full description

Bibliographic Details
Main Authors: Hisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya, Takaki Yoshikawa, Junichi Sakamoto, Taroh Satoh, on behalf of the HERBIS-2, HERBIS-4A and XParTS II Study Investigators
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
advanced gastric cancer
recurrent gastric cancer
S-1
capecitabine
cisplatin
Online Access:https://www.mdpi.com/2072-6694/14/22/5673

Internet

https://www.mdpi.com/2072-6694/14/22/5673

Similar Items